KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Operating Leases: 2019-2024

Historic Operating Leases for Acadia Pharmaceuticals (ACAD) over the last 6 years, with Dec 2024 value amounting to $42.0 million.

  • Acadia Pharmaceuticals' Operating Leases rose 6.44% to $43.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.0 million, marking a year-over-year increase of 6.44%. This contributed to the annual value of $42.0 million for FY2024, which is 12.06% down from last year.
  • As of FY2024, Acadia Pharmaceuticals' Operating Leases stood at $42.0 million, which was down 12.06% from $47.8 million recorded in FY2023.
  • Acadia Pharmaceuticals' 5-year Operating Leases high stood at $56.1 million for FY2021, and its period low was $42.0 million during FY2024.
  • Over the past 3 years, Acadia Pharmaceuticals' median Operating Leases value was $47.8 million (recorded in 2023), while the average stood at $47.5 million.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Operating Leases skyrocketed by 598.95% in 2020, and later declined by 12.06% in 2024.
  • Yearly analysis of 5 years shows Acadia Pharmaceuticals' Operating Leases stood at $44.5 million in 2020, then rose by 26.24% to $56.1 million in 2021, then fell by 6.11% to $52.7 million in 2022, then dropped by 9.29% to $47.8 million in 2023, then fell by 12.06% to $42.0 million in 2024.